Global Embryonic Stem Cell Market

Embryonic Stem Cell Comprehensive Study by Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Injuries and Wounds, Cardiovascular Disorders, Others (Drug Development and Discovery)), End Users (Medical care, Hospital, Laboratory) Players and Region - Global Market Outlook to 2030

Embryonic Stem Cell Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Embryonic Stem Cell
Embryonic stem cells are pluripotent, meaning they are able to grow into all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. These cells are distinguished by two distinctive properties: their pluripotency, and their ability to replicate indefinitely. Embryonic stem cells are pluripotent cells that have high proliferative capacity in culture and can be expanded through far more passages compared to adult stem cells without reaching senescence. The cells are isolated from the inner cell mass of blastocysts and can be differentiated towards numerous somatic cells with varying phenotypes.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR9.2%


The companies are focusing on advertising and marketing and ardent efforts being taken by them to create an awareness among people concerning the benefits of stem cells are likely to enhance the overall development of the market. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Embryonic Stem Cell market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

BioTime Inc. (United States), Cytori Therapeutics, Inc. (United States), STEMCELL Technologies Inc. (Canada), Astellas Pharma Inc. (Japan), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Caladrius Biosciences, Inc. (United States), Qiagen NV (Germany), Mesoblast Ltd. (Australia) and Geron (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pluristem Therapeutics (Israel), Pharmicell (South Korea), Holostem Terapie Avanzate (Italy) and Guanhao Biotech (China).

Segmentation Overview
AMA Research has segmented the market of Global Embryonic Stem Cell market by , Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Injuries and Wounds, Cardiovascular Disorders and Others [Drug Development and Discovery]) and Region.



On the basis of geography, the market of Embryonic Stem Cell has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Medical care will boost the Embryonic Stem Cell market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rapid Transition from Conventional Treatment Methods to Regenerative Medicine, Stem Cells-Banking is Gaining Importance and Increasing Awareness about Stem Cell Storage among People

Market Growth Drivers:
Growing Cases of Target Chronic Diseases and Increasing Disposable Income among Consumers

Challenges:
The Number of Successful Treatment Outcomes is Relatively Minor

Restraints:
Stem Cells Divide Uncontrollably, Which can Form Tumors

Opportunities:
Rising Investments for Research Activities and Development of Healthcare Industry in Emerging Economies

Market Leaders and their expansionary development strategies
In July 2020, Thermo Fisher Scientific Inc. and QIAGEN N.V. entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.
January 23, 2019: STEMCELL Technologies Launches mTeSR Plus, a Next-Generation Culture System for Human ES and iPS Cell Maintenance. This will help to avoid conditions that have been associated with DNA damage, genomic instability, and growth arrest in hPSCs. With the launch of mTeSR Plus, STEMCELL is positioned to set new industry standards in the pluripotent stem cell research field.
Regulation of stem cell research in the United Kingdom: Human tissue held for a specific research project approved by a recognised Research Ethics Committee (REC) (or where approval is pending). (Section 1 (9) of the Human Tissue Act 2004). The ethical approval is delivered by a Research Ethics Committee (REC) and it must be applied for using the guidance provided by National Research Ethics Service (NRES) at the Health Research Authority

Key Target Audience
Manufacturers of Embryonic Stem Cell, Healthcare Industry, Stem Cell Banks and Tissue Banks, Clinical Research Organizations, Research and Development Organization and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Neurological Disorders
  • Orthopedic Treatments
  • Oncology Disorders
  • Diabetes
  • Injuries and Wounds
  • Cardiovascular Disorders
  • Others [Drug Development and Discovery]
By End Users
  • Medical care
  • Hospital
  • Laboratory

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Cases of Target Chronic Diseases
      • 3.2.2. Increasing Disposable Income among Consumers
    • 3.3. Market Challenges
      • 3.3.1. The Number of Successful Treatment Outcomes is Relatively Minor
    • 3.4. Market Trends
      • 3.4.1. Rapid Transition from Conventional Treatment Methods to Regenerative Medicine
      • 3.4.2. Stem Cells-Banking is Gaining Importance
      • 3.4.3. Increasing Awareness about Stem Cell Storage among People
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Embryonic Stem Cell, by Application, End Users and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Embryonic Stem Cell (Value)
      • 5.2.1. Global Embryonic Stem Cell by: Application (Value)
        • 5.2.1.1. Neurological Disorders
        • 5.2.1.2. Orthopedic Treatments
        • 5.2.1.3. Oncology Disorders
        • 5.2.1.4. Diabetes
        • 5.2.1.5. Injuries and Wounds
        • 5.2.1.6. Cardiovascular Disorders
        • 5.2.1.7. Others [Drug Development and Discovery]
      • 5.2.2. Global Embryonic Stem Cell by: End Users (Value)
        • 5.2.2.1. Medical care
        • 5.2.2.2. Hospital
        • 5.2.2.3. Laboratory
      • 5.2.3. Global Embryonic Stem Cell Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Embryonic Stem Cell (Price)
  • 6. Embryonic Stem Cell: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BioTime Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cytori Therapeutics, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. STEMCELL Technologies Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astellas Pharma Inc. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lonza Group (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takara Bio Inc. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Caladrius Biosciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Qiagen NV (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mesoblast Ltd. (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Geron (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Embryonic Stem Cell Sale, by Application, End Users and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Embryonic Stem Cell (Value)
      • 7.2.1. Global Embryonic Stem Cell by: Application (Value)
        • 7.2.1.1. Neurological Disorders
        • 7.2.1.2. Orthopedic Treatments
        • 7.2.1.3. Oncology Disorders
        • 7.2.1.4. Diabetes
        • 7.2.1.5. Injuries and Wounds
        • 7.2.1.6. Cardiovascular Disorders
        • 7.2.1.7. Others [Drug Development and Discovery]
      • 7.2.2. Global Embryonic Stem Cell by: End Users (Value)
        • 7.2.2.1. Medical care
        • 7.2.2.2. Hospital
        • 7.2.2.3. Laboratory
      • 7.2.3. Global Embryonic Stem Cell Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Embryonic Stem Cell (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Embryonic Stem Cell: by Application(USD Million)
  • Table 2. Embryonic Stem Cell Neurological Disorders , by Region USD Million (2018-2023)
  • Table 3. Embryonic Stem Cell Orthopedic Treatments , by Region USD Million (2018-2023)
  • Table 4. Embryonic Stem Cell Oncology Disorders , by Region USD Million (2018-2023)
  • Table 5. Embryonic Stem Cell Diabetes , by Region USD Million (2018-2023)
  • Table 6. Embryonic Stem Cell Injuries and Wounds , by Region USD Million (2018-2023)
  • Table 7. Embryonic Stem Cell Cardiovascular Disorders , by Region USD Million (2018-2023)
  • Table 8. Embryonic Stem Cell Others [Drug Development and Discovery] , by Region USD Million (2018-2023)
  • Table 9. Embryonic Stem Cell: by End Users(USD Million)
  • Table 10. Embryonic Stem Cell Medical care , by Region USD Million (2018-2023)
  • Table 11. Embryonic Stem Cell Hospital , by Region USD Million (2018-2023)
  • Table 12. Embryonic Stem Cell Laboratory , by Region USD Million (2018-2023)
  • Table 13. South America Embryonic Stem Cell, by Country USD Million (2018-2023)
  • Table 14. South America Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 15. South America Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 16. Brazil Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 17. Brazil Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 18. Argentina Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 19. Argentina Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 20. Rest of South America Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 21. Rest of South America Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 22. Asia Pacific Embryonic Stem Cell, by Country USD Million (2018-2023)
  • Table 23. Asia Pacific Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 24. Asia Pacific Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 25. China Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 26. China Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 27. Japan Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 28. Japan Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 29. India Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 30. India Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 31. South Korea Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 32. South Korea Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 33. Taiwan Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 34. Taiwan Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 35. Australia Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 36. Australia Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 38. Rest of Asia-Pacific Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 39. Europe Embryonic Stem Cell, by Country USD Million (2018-2023)
  • Table 40. Europe Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 41. Europe Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 42. Germany Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 43. Germany Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 44. France Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 45. France Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 46. Italy Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 47. Italy Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 48. United Kingdom Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 49. United Kingdom Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 50. Netherlands Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 51. Netherlands Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 52. Rest of Europe Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 53. Rest of Europe Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 54. MEA Embryonic Stem Cell, by Country USD Million (2018-2023)
  • Table 55. MEA Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 56. MEA Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 57. Middle East Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 58. Middle East Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 59. Africa Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 60. Africa Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 61. North America Embryonic Stem Cell, by Country USD Million (2018-2023)
  • Table 62. North America Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 63. North America Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 64. United States Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 65. United States Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 66. Canada Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 67. Canada Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 68. Mexico Embryonic Stem Cell, by Application USD Million (2018-2023)
  • Table 69. Mexico Embryonic Stem Cell, by End Users USD Million (2018-2023)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Embryonic Stem Cell: by Application(USD Million)
  • Table 81. Embryonic Stem Cell Neurological Disorders , by Region USD Million (2025-2030)
  • Table 82. Embryonic Stem Cell Orthopedic Treatments , by Region USD Million (2025-2030)
  • Table 83. Embryonic Stem Cell Oncology Disorders , by Region USD Million (2025-2030)
  • Table 84. Embryonic Stem Cell Diabetes , by Region USD Million (2025-2030)
  • Table 85. Embryonic Stem Cell Injuries and Wounds , by Region USD Million (2025-2030)
  • Table 86. Embryonic Stem Cell Cardiovascular Disorders , by Region USD Million (2025-2030)
  • Table 87. Embryonic Stem Cell Others [Drug Development and Discovery] , by Region USD Million (2025-2030)
  • Table 88. Embryonic Stem Cell: by End Users(USD Million)
  • Table 89. Embryonic Stem Cell Medical care , by Region USD Million (2025-2030)
  • Table 90. Embryonic Stem Cell Hospital , by Region USD Million (2025-2030)
  • Table 91. Embryonic Stem Cell Laboratory , by Region USD Million (2025-2030)
  • Table 92. South America Embryonic Stem Cell, by Country USD Million (2025-2030)
  • Table 93. South America Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 94. South America Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 95. Brazil Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 96. Brazil Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 97. Argentina Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 98. Argentina Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 99. Rest of South America Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 100. Rest of South America Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 101. Asia Pacific Embryonic Stem Cell, by Country USD Million (2025-2030)
  • Table 102. Asia Pacific Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 103. Asia Pacific Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 104. China Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 105. China Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 106. Japan Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 107. Japan Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 108. India Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 109. India Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 110. South Korea Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 111. South Korea Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 112. Taiwan Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 113. Taiwan Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 114. Australia Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 115. Australia Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 116. Rest of Asia-Pacific Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 117. Rest of Asia-Pacific Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 118. Europe Embryonic Stem Cell, by Country USD Million (2025-2030)
  • Table 119. Europe Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 120. Europe Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 121. Germany Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 122. Germany Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 123. France Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 124. France Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 125. Italy Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 126. Italy Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 127. United Kingdom Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 128. United Kingdom Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 129. Netherlands Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 130. Netherlands Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 131. Rest of Europe Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 132. Rest of Europe Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 133. MEA Embryonic Stem Cell, by Country USD Million (2025-2030)
  • Table 134. MEA Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 135. MEA Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 136. Middle East Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 137. Middle East Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 138. Africa Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 139. Africa Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 140. North America Embryonic Stem Cell, by Country USD Million (2025-2030)
  • Table 141. North America Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 142. North America Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 143. United States Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 144. United States Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 145. Canada Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 146. Canada Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 147. Mexico Embryonic Stem Cell, by Application USD Million (2025-2030)
  • Table 148. Mexico Embryonic Stem Cell, by End Users USD Million (2025-2030)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Embryonic Stem Cell: by Application USD Million (2018-2023)
  • Figure 5. Global Embryonic Stem Cell: by End Users USD Million (2018-2023)
  • Figure 6. South America Embryonic Stem Cell Share (%), by Country
  • Figure 7. Asia Pacific Embryonic Stem Cell Share (%), by Country
  • Figure 8. Europe Embryonic Stem Cell Share (%), by Country
  • Figure 9. MEA Embryonic Stem Cell Share (%), by Country
  • Figure 10. North America Embryonic Stem Cell Share (%), by Country
  • Figure 11. Global Embryonic Stem Cell share by Players 2023 (%)
  • Figure 12. Global Embryonic Stem Cell share by Players (Top 3) 2023(%)
  • Figure 13. Global Embryonic Stem Cell share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. BioTime Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. BioTime Inc. (United States) Revenue: by Geography 2023
  • Figure 17. Cytori Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Cytori Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 19. STEMCELL Technologies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 20. STEMCELL Technologies Inc. (Canada) Revenue: by Geography 2023
  • Figure 21. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 23. Lonza Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Lonza Group (Switzerland) Revenue: by Geography 2023
  • Figure 25. Takara Bio Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Takara Bio Inc. (Japan) Revenue: by Geography 2023
  • Figure 27. Caladrius Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Caladrius Biosciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Qiagen NV (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Qiagen NV (Germany) Revenue: by Geography 2023
  • Figure 31. Mesoblast Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 32. Mesoblast Ltd. (Australia) Revenue: by Geography 2023
  • Figure 33. Geron (United States) Revenue, Net Income and Gross profit
  • Figure 34. Geron (United States) Revenue: by Geography 2023
  • Figure 35. Global Embryonic Stem Cell: by Application USD Million (2025-2030)
  • Figure 36. Global Embryonic Stem Cell: by End Users USD Million (2025-2030)
  • Figure 37. South America Embryonic Stem Cell Share (%), by Country
  • Figure 38. Asia Pacific Embryonic Stem Cell Share (%), by Country
  • Figure 39. Europe Embryonic Stem Cell Share (%), by Country
  • Figure 40. MEA Embryonic Stem Cell Share (%), by Country
  • Figure 41. North America Embryonic Stem Cell Share (%), by Country
List of companies from research coverage that are profiled in the study
  • BioTime Inc. (United States)
  • Cytori Therapeutics, Inc. (United States)
  • STEMCELL Technologies Inc. (Canada)
  • Astellas Pharma Inc. (Japan)
  • Lonza Group (Switzerland)
  • Takara Bio Inc. (Japan)
  • Caladrius Biosciences, Inc. (United States)
  • Qiagen NV (Germany)
  • Mesoblast Ltd. (Australia)
  • Geron (United States)
Additional players considered in the study are as follows:
Pluristem Therapeutics (Israel) , Pharmicell (South Korea) , Holostem Terapie Avanzate (Italy) , Guanhao Biotech (China)
Select User Access Type

Key Highlights of Report


Apr 2024 151 Pages 80 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Embryonic Stem Cell Market Quantitative research analysis
Global Embryonic Stem Cell Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as BioTime Inc. (United States), Cytori Therapeutics, Inc. (United States), STEMCELL Technologies Inc. (Canada), Astellas Pharma Inc. (Japan), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Caladrius Biosciences, Inc. (United States), Qiagen NV (Germany), Mesoblast Ltd. (Australia) and Geron (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rapid Transition from Conventional Treatment Methods to Regenerative Medicine " is seen as one of major influencing trends for Embryonic Stem Cell Market during projected period 2023-2030.
The Embryonic Stem Cell market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Embryonic Stem Cell Market Report?

Have a Query? Click Here

Other Related Reports

Probiotic Comprehensive Study by Application (Food and Beverages, Dietary Supplements, Animal Feed), Strains (Animalis, Breve, Lactis (Buttermilk, Cottage cheese, other cheeses), Longum, Acidophilus,...
$ 3750
D-Ribose Comprehensive Study by Type (Food Grade D-Ribose, Pharmaceutical Grade D-Ribose), Application (Pharmaceutical Intermediate, Food Additives, Sports Supplement, Health Products), Form (Crystal...
$ 3650
Medicinal Cannabis Comprehensive Study by Type (Flowers, Concentrates, Others), Application (Hospitals, Clinics, Medical Research Centers), Distribution Channel (Dispensaries, Pharmacies, Online Reta...
$ 3650
Narcotic Analgesics Comprehensive Study by Type (Oxycodone, Fentanyl, Hydrocodone, Hydromorphone, Morphine, Methadone, Oxymorphone, Pentazocine), Form (Natural, Semi-Synthetic, Synthetic), Distributi...
$ 3650
Topical Analgesics Comprehensive Study by Type (Prescription Pain Relief, Over-The-Counter Pain Relief), Distribution Channel (Pharmacies & Drug Stores, E-Commerce, Retail & Grocery Stores), Formulat...
$ 3450
Functional Powder Drinks Comprehensive Study by Type (Organic, Conventional), Distribution Channel (Online Stores, Hypermarket/Supermarket, Offline Retail Stores, Other Convenience Stores), Ingredien...
$ 3650